Cargando…

Long‐term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: Open‐label extension of a randomized clinical study

OBJECTIVE: This study was undertaken to examine long‐term (up to 7.8 years) retention rate, safety, and tolerability of the antiseizure medication (ASM) cenobamate as adjunctive treatment in the open‐label extension (OLE) of study YKP3089C013 (C013; ClinicalTrials.gov: NCT01397968). METHODS: Patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	French, Jacqueline A., Chung, Steve S., Krauss, Gregory L., Lee, Sang Kun, Maciejowski, Maciej, Rosenfeld, William E., Sperling, Michael R., Kamin, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Full‐length Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456960/ https://www.ncbi.nlm.nih.gov/pubmed/34254673 http://dx.doi.org/10.1111/epi.17007

Ejemplares similares

Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures
por: Chung, Steve S., et al.
Publicado: (2020)

Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open‐label safety study
por: Sperling, Michael R., et al.
Publicado: (2020)

Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open‐label study
por: Sperling, Michael R., et al.
Publicado: (2021)

Post hoc analysis of a phase 3, multicenter, open‐label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications
por: Rosenfeld, William E., et al.
Publicado: (2021)

Long-term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures
por: Klein, Pavel, et al.
Publicado: (2022)

Critical Appraisal of Cenobamate as Adjunctive Treatment of Focal Seizures in Adults
por: Zaccara, Gaetano, et al.
Publicado: (2021)

Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis
por: Lattanzi, Simona, et al.
Publicado: (2020)

Effectiveness and safety of adjunctive cenobamate for focal seizures in adults with developmental disability treated in clinical practice
por: Connor, Gregory S., et al.
Publicado: (2022)

Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of Phase II and Phase III double‐blind and open‐label extension studies in India
por: Mehndiratta, Man M., et al.
Publicado: (2021)

Assessment of the long‐term efficacy and safety of adjunctive perampanel in tonic‐clonic seizures: Analysis of four open‐label extension studies
por: Rektor, Ivan, et al.
Publicado: (2020)

Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial
por: Sperling, Michael R, et al.
Publicado: (2015)

Open‐label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic‐clonic seizures
por: Fogarasi, Andras, et al.
Publicado: (2020)

Cenobamate for treatment-resistant focal seizures: current evidence and place in therapy
por: Singh, Alok
Publicado: (2022)

Long‐term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program
por: Sander, Josemir W., et al.
Publicado: (2021)

Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial‐onset seizures: A randomized historical‐control phase III study based in North America
por: Sperling, Michael R., et al.
Publicado: (2015)

Evidence for long memory in focal seizure duration
por: Fan, Joline M., et al.
Publicado: (2021)

Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307
por: Krauss, Gregory L, et al.
Publicado: (2014)

Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089)
por: Kasteleijn- Nolst Trenite, Dorothee G.A., et al.
Publicado: (2019)

Real‐world safety and effectiveness of cenobamate in patients with focal onset seizures: Outcomes from an Expanded Access Program
por: Villanueva, Vicente, et al.
Publicado: (2023)

Once-daily USL255 as adjunctive treatment of partial-onset seizures: Randomized phase III study
por: Chung, Steve S, et al.
Publicado: (2014)

Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double‐blind, phase III studies
por: Steinhoff, Bernhard J., et al.
Publicado: (2020)

Cognitive effects of adjunctive perampanel for partial‐onset seizures: A randomized trial
por: Meador, Kimford J., et al.
Publicado: (2016)

Cost-effectiveness of perampanel as an adjunctive treatment for uncontrolled focal seizures in pediatric patients: a Chinese perspective
por: Hu, Yani, et al.
Publicado: (2022)

Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes
por: French, Jacqueline, et al.
Publicado: (2016)

Remarkably High Efficacy of Cenobamate in Adults With Focal-Onset Seizures: A Double-Blind, Randomized, Placebo-Controlled Trial
por: Vossler, David G.
Publicado: (2020)

Long‐term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open‐label extension study
por: Trinka, Eugen, et al.
Publicado: (2020)

Impact of diagnostic delay on seizure outcome in newly diagnosed focal epilepsy
por: Parviainen, Laura, et al.
Publicado: (2020)

Fenfluramine HCl (Fintepla(®)) provides long‐term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open‐label extension study
por: Sullivan, Joseph, et al.
Publicado: (2020)

Anticonvulsant effects of cenobamate in chemically and electrically induced seizure models in rodents
por: Melnick, Susan M., et al.
Publicado: (2023)

Real‐world experience with direct brain‐responsive neurostimulation for focal onset seizures
por: Razavi, Babak, et al.
Publicado: (2020)

Anti-Seizure Activity of 1-Adamantane Carboxylic Acid in Common Experimental Seizure Models: Role of Benzodiazepine-GABA(A) Receptors
por: Ghanbari, Elham, et al.
Publicado: (2021)

Incidence of seizure exacerbation and seizures reported as adverse events during adjunctive treatment with eslicarbazepine acetate: A pooled analysis of three Phase III controlled trials
por: Carreño, Mar, et al.
Publicado: (2017)

Understanding the burden of focal epilepsy as a function of seizure frequency in the United States, Europe, and Brazil
por: Gupta, Shaloo, et al.
Publicado: (2017)

Focal to bilateral tonic–clonic seizures are associated with widespread network abnormality in temporal lobe epilepsy
por: Sinha, Nishant, et al.
Publicado: (2021)

Recombinant activated factor VII for uncontrolled bleeding postcardiac surgery
por: Habib, Aly Makram, et al.
Publicado: (2016)

Efficacy and safety of perampanel monotherapy in patients with focal‐onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: The open‐label Study 342 (FREEDOM Study)
por: Yamamoto, Takamichi, et al.
Publicado: (2020)

Pregabalin as adjunctive therapy in adult and pediatric patients with generalized tonic‐clonic seizures: A randomized, placebo‐controlled trial
por: Driscoll, Joseph, et al.
Publicado: (2021)

Detection of generalized tonic–clonic seizures using surface electromyographic monitoring
por: Halford, Jonathan J., et al.
Publicado: (2017)

Dose Adjustment of Concomitant Antiseizure Medications During Cenobamate Treatment: Expert Opinion Consensus Recommendations
por: Smith, Michael C., et al.
Publicado: (2022)

Clinical utility of implantable neurostimulation devices as adjunctive treatment of uncontrolled seizures
por: Cox, Joanna H, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_hcbimn5uqo3f0o0bflqv9bu5u2